electroCore Q2 Earnings Call Highlights

Impact · against what's priced in

electroCore shows strong top-line momentum and a clearer path to profitability, though regulatory delays for Quell 2.0 and rising customer acquisition costs for Truvaga act as headwinds. The revenue guidance raise and EBITDA targets suggest operational scaling is working, but regulatory uncertainty remains the primary risk to the growth trajectory.

ECOR+0.30

No priced-in read yet

In context

The company raised its full-year revenue outlook to >30% growth and set a target for positive adjusted EBITDA by Q3 2027 without dilutive funding. While Quell sales grew 700% to $1.3 million, an FDA Form 483 will delay the Quell 2.0 relaunch and Truvaga's customer acquisition costs are rising due to increased competition.

• healthcare▲20%
• revenue growth▲13%
• guidance▲5%
• earnings
• ECOR
• direct to consumer
• ebitda